Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny sensor tracks blood sugar in preterm babies to boost brain health

NCT ID NCT05436925

Knowledge-focused Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study placed a continuous glucose monitor (CGM) on 24 preterm infants born before 31 weeks to track their blood sugar levels for up to 10 days. The goal was to see how well the device detects high and low blood sugar, and to link those readings to the babies' growth and brain development over time. The CGM was used for research only, not to guide treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dexcom G6 continuous glucose monitor (CGM)
What this could lead to
If successful, this could help doctors better manage blood sugar in preterm infants, potentially improving their growth and brain development.
What could go wrong
This is a small, early-stage study with only 24 infants, so results may not apply to all preterm babies. The CGM is used for research only, not for diagnosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

24 people

The number who actually took part.

Started

Oct 2022

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Preterm infants (gestational age (GA) at birth \<31 weeks) admitted to the University of Minnesota Masonic Children's Hospital

Ages

Up to 72 hours

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * preterm infants (gestational age (GA) at birth \< 31 weeks) * admitted to the University of Minnesota Masonic Children's Hospital Neonatal Intensive Care Unit * written informed consent can be secured from a parent within 96 hours of birth. Exclusion Criteria: * Infants born at ≥31 weeks GA * infants with a prenatally diagnosed clinical or genetic condition (other than prematurity) that is known to affect growth rate, adiposity, or neurocognitive development * children experiencing severe birth asphyxia, * children enrolled in another nutritional study, * children likely to be transferred out of the NICU

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperglycemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperglycemia hypoglycemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperglycemia Very low birth weight infant Very preterm maturity of infant

Contacts and locations

Locations

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.